Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 8,158 matching trials from the live ClinicalTrials.gov search.
Filters: Phoenix, Arizona Clear all
Completed Phase 2 Interventional

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

NCT00402077
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate, sibutramine, phentermine, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Phase 1 Interventional

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

NCT03889912
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Interventions
Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

NCT01298219
View directory record Official record
Conditions
Opioid-induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
115
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

NCT00045630
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
carboplatin, gemcitabine, paclitaxel, surgery
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
128
States / cities
Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 31, 2026, 4:44 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 31, 2026, 4:44 PM EDT
Completed No phase listed Observational

A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment

NCT00702065
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Phoenix, Arizona • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

NCT03486834
View directory record Official record
Conditions
Cytomegalovirus (CMV) Infections
Interventions
V160, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 35 Years · Female only
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
54
States / cities
Birmingham, Alabama • Chandler, Arizona • Rialto, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Different Carbohydrate Feedings on a Hydrogen Breath Curve and Self-reported Gastrointestinal Complaints

NCT06648967
View directory record Official record
Conditions
Quality of Life
Interventions
Supplementation with a multi-ingredient whey supplement
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 31, 2026, 4:44 PM EDT
Terminated Phase 3 Interventional

Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)

NCT02074007
View directory record Official record
Conditions
Acute Otitis Media
Interventions
AR01, Placebo Comparator
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
2 Months to 18 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Phoenix, Arizona • Bakersfield, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant

NCT00099736
View directory record Official record
Conditions
Kidney Transplantation
Interventions
FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
42
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 31, 2026, 4:44 PM EDT
Enrolling by invitation Not applicable Interventional

A Web-Based Tool to Help People With Health Conditions Make Contraceptive Decisions

NCT07075536
View directory record Official record
Conditions
Contraceptive Usage, Contraceptive Behavior, Chronic Disease, Chronic Condition, Chronic Conditions, Multiple
Interventions
My Health, My Choice Web-Based Contraceptive Decision Tool, Usual Contraceptive Care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Pomona, California • Nampa, Idaho + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 4:44 PM EDT
Recruiting Phase 3 Interventional

An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin

NCT07845071
View directory record Official record
Conditions
Pain
Interventions
Cebranopadol 400 ug
Drug
Lead sponsor
Adneuris Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Riverside, California • Longmont, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 4:44 PM EDT
Not yet recruiting Not applicable Interventional

Mixed-Reality Visual Attention Task for Neglect Diagnosis and Rehabilitation

NCT07227844
View directory record Official record
Conditions
Neglect, Sensory, Neglect, Hemispatial, Neglect, Hemisensory
Interventions
VR Neglect Training
Device
Lead sponsor
Markey Olson
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

NCT02207634
View directory record Official record
Conditions
Dyslipidemia
Interventions
Evolocumab, Placebo, Background Statin Therapy
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
134
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 123 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 31, 2026, 4:44 PM EDT
Terminated Phase 3 Interventional Results available

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

NCT03071692
View directory record Official record
Conditions
Type2 Diabetes, Dyslipidemia
Interventions
K-877, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
242
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 192 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 31, 2026, 4:44 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07690371
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy

NCT00895011
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Placebo, Avanafil
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
51
States / cities
Phoenix, Arizona • Laguna Hills, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Not applicable Interventional Results available

Medtronic CoreValve Evolut R U.S. Clinical Study

NCT02207569
View directory record Official record
Conditions
Aortic Stenosis
Interventions
CoreValve Evolut R TAVR system
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Phase 1 Interventional

Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer

NCT00005022
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
242
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 31, 2026, 4:44 PM EDT
Active, not recruiting Phase 2 Interventional

Conditioning SCID Infants Diagnosed Early

NCT03619551
View directory record Official record
Conditions
SCID
Interventions
Busulfan, Cell processing for TCRαβ+/CD19+ depletion
Drug · Device
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
0 Years to 2 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain

NCT01452529
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Hydrocodone bitartrate q24h film-coated tablets, Placebo to match hydrocodone bitartrate q24h tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets

NCT01922739
View directory record Official record
Conditions
Low Back Pain
Interventions
Hydrocodone ER, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 31, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

NCT02217475
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Cenicriviroc, Placebo
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
40
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 31, 2026, 4:44 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

NCT04201457
View directory record Official record
Conditions
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
Interventions
Dabrafenib, Trametinib, Hydroxychloroquine
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
1 Year to 30 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 31, 2026, 4:44 PM EDT